Betting on the liver disease treatment track, Novo Nordisk makes a hefty $5.2 billion acquisition of Akero
```
Novo Nordisk has agreed to acquire U.S. biotechnology company Akero Therapeutics for up to $5.2 billion, aiming to secure a promising liver disease drug and further expand its presence in the treatment of obesity-related metabolic diseases to counter increasingly fierce market competition.
On Thursday, the Danish pharmaceutical giant